Drug Profile

AK 001

Alternative Names: AK001

Latest Information Update: 28 Oct 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Johns Hopkins University School of Medicine
Developer Allakos
Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibodies; Skin disorder therapies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Oct 2018 No recent reports of development identified for phase-I development in Allergy in USA (Parenteral)
01 Jan 2018 Allakos completes a phase II trial in Nasal polyps (Combination therapy) in United Kingdom, Spain, Netherlands, Germany, Belgium, USA (IV) (NCT02734849)
01 Jan 2017 Discontinued - Phase-I for Hypersensitivity in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com